Genomic surveillance: a potential shortcut for effective Chagas disease management

Chagas disease is an enduring public health issue in many Latin American countries, receiving insufficient investment in research and development. Strategies for disease control and management currently lack efficient pharmaceuticals, commercial diagnostic kits with improved sensitivity, and vaccines. Genetic heterogeneity of Trypanosoma cruzi is a key aspect for novel drug design since pharmacological technologies rely on the degree of conservation of parasite target proteins. Therefore, there is a need to expand the knowledge regarding parasite genetics which, if fulfilled, could leverage Chagas disease research and development, and improve disease control strategies. The growing capacity of whole-genome sequencing technology and its adoption as disease surveillance routine may be key for solving this long-lasting problem.

恰加斯病（Chagas disease）是长期困扰诸多拉丁美洲国家的公共卫生难题，相关研发投入始终不足。当前的疾病防控与管理策略仍缺乏高效治疗药物、灵敏度更优的商用诊断试剂盒以及疫苗。克氏锥虫（Trypanosoma cruzi）的遗传异质性是新型药物研发的关键考量因素，因为药物开发技术依赖于寄生虫靶标蛋白的保守程度。因此，有必要深化对该寄生虫遗传学特征的认知；若能实现这一目标，将可推动恰加斯病的研发进程，并优化疾病防控策略。全基因组测序技术的性能持续提升，且其逐步被应用于疾病监测的常规流程，这或为解决这一长期存在的公共卫生难题提供关键突破口。